



JOINT SCIENTIFIC SYMPOSIUM

ADVANCES IN THERANOSTICS OF RARE CANCER

September 5th, 2014

MEDIZINISCHE UNIVERSITÄT INNSBRUCK

Great Lecture Hall MZA

Anichstraße 35, 6020

Innsbruck, Austria

Medizinische Fakultät Mannheim
der Universität Heidelberg

Universitätsklinikum Mannheim



EUROPEAN INSTITUTE
FOR BIOMEDICAL
IMAGING RESEARCH



MEDIZINISCHE
UNIVERSITÄT
INNSBRUCK

WELCOME ADDRESS

Patients with malignant rare diseases require a personalized diagnostic work-up in a highly interdisciplinary approach. With the advent of tracers for positron emission tomography (PET) with increasing specificity the susceptibility to targeted therapies, early measurement of response as well as mechanisms of resistance can be visualized. This provides the basis for a minimally-invasive treatment of metastatic disease with systemic endoradiotherapeutic approaches and image-guided interventional ablative methods.

Neuroendocrine tumours (NET) represent the role model for a personalized theranostic approach, i.e. utilizing the same target-specific mechanisms for molecular imaging and treatment. PET imaging of the somatostatin receptor family with ⁶⁸Gallium-based tracers in combination with ⁹⁰Yttrium-based endoradiopharmaceuticals allow effective tumour control even in the metastatic disease stage. Optimized visualization of the extent of disease along with refined models for dosimetry has substantially increased the effectiveness of this treatment while minimizing side effects.

Gastrointestinal stromal tumours (GIST) represent another entity of rare malignancies with a high potential for minimally-invasive treatment on the basis of molecular imaging. While fundamental breakthroughs have been achieved with regard to molecular characterization of tumour resistance to the current class of targeted agents, the tyrosine kinase inhibitors, little progress has been made in the field of alternative treatment options. The EU FP7 project MITIGATE aims at systematically addressing this need by developing new molecular imaging and treatment approaches through an interdisciplinary team of scientists from the fields of molecular pathology, biology, chemistry, radiochemistry, physics, engineering, interventional radiology, nuclear medicine and surgery.

The scope of this exciting meeting is to inform clinicians about the current state-of-the-art treatment options in NET, explain fundamental principles for targeted molecular imaging, elude mechanism of resistance in GIST as well as show the value of multimodal treatment in oligometastatic disease. We are cordially inviting every clinician and scientist with interest in this dynamic field of research and are looking forward to welcome you to the beautiful city of Innsbruck.

Scientific Leadership

Univ.-Prof. Dr. med.

Stefan Schönberg

Director of the Institute of
Clinical Radiology and
Nuclear Medicine (IKRN),
University Medical Center
Mannheim, Medical Faculty
Mannheim, Heidelberg
University

o.Univ.-Prof. Dr. med.

Werner Jaschke

Director, Department of
Radiology, Innsbruck
Medical University

Organising committee

Dr. Pamela Zolda (**EIBIR**)
Dr. Dominika Adams (**UHEI**)
Ing. Ursula Jürschik (**MUI**)



The symposium has
been accredited by;

**Ärzt e k a m m e r
Ö s t e r r e i c h**

with **10 DFP** points.

AGENDA

Morning session

Progress in Diagnosis and Therapy of Abdominal Neuroendocrine Tumour (NET)

Moderators: Univ.-Prof. Dr. med. S. Schönberg, Univ.-Prof. Dr. med. W. Jaschke

- 8:30-8:40 Welcome address
- 8:40-9:10 Diagnostics of NET treatment options: which type of treatment is relevant for specific tumour stages?
Ass. Prof. Dr. med. Hubert Schwaighofer
- 9:20-9:50 Radiopharmaceuticals for NET: present view and perspective
Univ. Doz. Dr. Clemens Decristoforo
- 10:00-10:30 **COFFEE BREAK**
- Moderators:** Univ.-Prof. Dr. med. I. Virgolini, Univ.-Prof. Dr. med. W. Vogel
- 10:30-11:00 Nuclear Medicine in Diagnosis and Therapy
Univ.-Prof. Dr. med. Wolfgang Vogel
- 11:10-11:40 Stereotactic Radiofrequency Ablation for Liver Tumours
a.o.Univ.-Prof. Dr. med. Reto Bale

Afternoon session

Advances in Gastrointestinal Stromal Tumour (GIST)

Moderators: Univ.-Prof. Dr. S. Aime, Univ.-Prof. Dr. B. Wängler

- 13:30-14:00 Current therapeutic strategies in GIST
Univ.-Prof. Dr. med. Peter Hohenberger
- 14:10-14:55 Molecular pathology of GIST
Prof. Dr. med. Jonathan Fletcher
- 15:05-15:45 Mechanisms of therapeutic resistance in GIST
Univ.-Prof. Dr. med. Eva Wardelmann
- 15:45-16:15 **COFFEE BREAK**
- Moderators:** a.o.Univ.-Prof. Dr. med. R. Bale, Prof. Dr. med. J. Fletcher
- 16:15-16:45 Advances in molecular imaging of GIST
Univ.-Prof. Dr. Björn Wängler
- 16:55-17:25 GIST: Minimally-invasive treatment concepts in hepatic metastasing GIST
Prof. Dr. Steffen Diehl
- 17:35-17:50 The FP7 funded project: Closed-loop Molecular Environment for Minimally Invasive Treatment of Patients with Metastatic Gastrointestinal Stromal Tumours (MITIGATE)
Univ.-Prof. Dr. med. Stefan Schönberg
- 17:50-18:00 Conclusions

All talks will be followed by 10 minutes of discussion

LIST OF SPEAKERS & MODERATORS

Univ.-Prof. Dr. Silvio Aime

Molecular Biotechnology Center, Università degli Studi di Torino, Italy

a.o.Univ.-Prof. Dr. med. Reto Bale

Department of Radiology, Innsbruck Medical University

Univ. Doz. Dr. Clemens Decristoforo

Department of Nuclear Medicine, Innsbruck Medical University

Prof. Dr. med. Steffen Diehl

Institute of Clinical Radiology and Nuclear Medicine (IKRN), Section Chief Minimally-Invasive Therapy, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University

Prof. Dr. med. Jonathan Fletcher

Associate Professor, Department of Pathology and Department of Pediatrics, Harvard Medical School
Staff Medical and Pediatric Oncologist and Associate Pathologist, Pathology, Boston Children's Hospital
Clinical Associate, Pathology, Massachusetts General Hospital
Associate Pathologist, Pathology, Brigham And Women's Hospital

Univ.-Prof. Dr. med. Peter Hohenberger

Director of the Division of Surgical Oncology&Thoracic Surgery (SCO&TCH), University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University

o.Univ.-Prof. Dr. med. Werner Jaschke

Director, Department of Radiology, Innsbruck Medical University

Ass.-Prof. Dr. med. Hubert Schwaighofer

Department of Internal Medicine, Division of Gastroenterology and Hepatology, Innsbruck Medical University

Univ.-Prof. Dr. med. Irene Virgolini

Director, Department of Nuclear Medicine, Innsbruck Medical University

Univ.-Prof. Dr. med. Wolfgang Vogel

Department of Internal Medicine, Director of Division of Gastroenterology and Hepatology, Innsbruck Medical University

Univ.-Prof. Dr. med. Eva Wardelmann

Director of the Gerhard-Domagk-Institute for Pathology (GDI), Muenster University Hospital

Univ.-Prof. Dr. Björn Wängler

Institute of Clinical Radiology and Nuclear Medicine (IKRN), Molecular Imaging and Radiochemistry, Section Chief Clinical Radiopharmacy, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University

TRANSPORTATION

Taxi Service:

Tel. (+43) 0512 5311

Public Transportation:

Tram 3

Buslines C, F, J, M, O, R

Parking:

West-Garage (Beselepark, Entrance Innerkoflerstraße)

The MITIGATE project receives funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant no 602306

